The global Alzheimer’s disease therapeutics & diagnostics market was valued at $6840.31 million in 2021, and is expected to reach $12489.31 million by 2030, growing at a CAGR of 6.61% during the forecast period.
GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030
Global Alzheimer’s Disease Market by Therapeutics & Diagnostics (Therapeutics (Drugs, Disease Stage, Generic & Branded) Diagnostics (Lumbar Puncture Test, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Blood Test, Other Diagnostics)) by Geography
The global Alzheimer’s disease therapeutics & diagnostics market was valued at $6840.31 million in 2021, and is expected to reach $12489.31 million by 2030, growing at a CAGR of 6.61% during the forecast period.
To know more about this report, request a free sample copy
Alzheimer’s disease is one of the most common forms of dementia worldwide. Alzheimer’s disease (AD) is a chronic, degenerative disease that affects the brain’s nerve cells, or neurons, causing memory loss, cognitive and linguistic impairment, and behavioral changes. Disease-modifying medications and a large number of late-stage pipeline pharmaceuticals are expected to boost the market growth.
Read our latest blog on the Alzheimer’s Disease Therapeutics & Diagnostics Market
Key growth enablers of the global Alzheimer’s disease therapeutics & diagnostics market:
- Growing geriatric population
- Rising pervasiveness of Alzheimer’s disease
- Alzheimer’s disease (AD) is becoming a major public health threat due to the increasing number of affected individuals. The high prevalence of Alzheimer’s disease globally is a key driver for the market and emphasizes a vital need to develop an effective treatment.
- For example, according to the Alzheimer’s disease facts and figures, it is estimated that a new case occurs every 33 seconds. According to Translational Research & Clinical Intervention, 5.3 million Americans and 35 million people worldwide suffer from Alzheimer’s disease.
- Emerging novel diagnostic technologies
- Increasing pipeline drugs
Key growth restraining factors of the market:
- Failure of the late-stage drugs
- For the past 14 years, researchers have been unsuccessful in pursuing an Alzheimer’s disease pharmacological treatment. The contemporary age of Alzheimer’s drug development began in 1984 when the cholinergic hypothesis of memory impairment was proposed. Merely 4 cholinesterase inhibitors and memantine have proven efficacy against the progression of Alzheimer’s disease since then, despite evaluating countless possible treatments and medications in clinical studies.
- In 2018, there were 31 medications in Phase I clinical trials and 68 pharmaceuticals in Phase II clinical trials. Twelve of the 31 medicines in phase III are symptomatic, and 19 are disease-modifying. In addition, seven medicines are being tested in Alzheimer’s disease preventative trials.
- Stringent government regulations
- Lack of the availability of surrogate markers
Global Alzheimer’s Disease Therapeutics & Diagnostics Market | Top Trends
- Usage of Computed Tomography (CT) in diagnosing Alzheimer’s disease is on the rise. CT is one of the advanced and cost-effective diagnostic tests used to diagnose Alzheimer’s. According to Medscape Organization, a CT scan is approximately 20% less expensive than an MRI scan.
- Several novel diagnostics technologies have been discovered for AD, including the invention that identifies mutated proteins in sub-cellular compartments and describes these mutations that lead to redistribution of crucial cellular organelles. Alteration of organelles distribution can serve as a powerful diagnostic tool, an assay to screen novel therapeutic compounds for Alzheimer’s disease.
- Various private firms and government organizations are investing in advancing biomarkers for Alzheimer’s treatment. For instance, Alzheimer’s Drug Discovery Foundation granted a new fund for the treatments and biomarkers with a total of about $1.5 million.
Market Segmentation – Therapeutics & Diagnostics –
Market by Therapeutics & Diagnostics:
- Therapeutics
- Drugs
- Marketed Drugs
- Pipeline Drugs
- Disease Stage
- Late-Stage: Severe AD
- The majority of market share was held by late-stage: severe AD in 2021. According to alz.org, the US Food and Drug Administration (FDA) has licensed memantine (Namenda) & cholinesterase inhibitors (Razadyne, Exelon, Aricept) as late-stage medications to treat cognitive symptoms (confusion, memory loss, and problems with thinking and reasoning).
- Early/Middle Stage: Mild to Moderate AD
- Prodromal Stage
- Generic & Branded
- Branded
- Generic
- Drugs
- Diagnostics
- Lumbar Puncture Test
- Positron Emission Tomography
- Electroencephalography
- Magnetic Resonance Imaging
- Computed Tomography
- Blood Test
- Blood tests are expected to be the market’s fastest-growing diagnostics. Blood testing is a new tool that might help researchers detect Alzheimer’s disease before it starts or in those already displaying signs of dementia. The method could be less intrusive and expensive than existing brain scans and spinal fluid studies, allowing for earlier treatment and the testing of new medicines.
- For instance, an international team of researchers led by HKUST created a simple yet reliable blood test from Chinese clinical information for the first time, with an average precision of over 96 percent, for early identification and screening of Alzheimer’s disease (AD).
- Other Diagnostics
Geographical Study based on Four Major Regions:
- North America: The United States and Canada
- Because of a big patient pool and excellent diagnostic rates, North America leads the industry and is a prominent participant in Alzheimer’s disease therapeutics and diagnostics adoption. The United States is a major market player. According to the National Institutes of Health, 5.8 million Americans had Alzheimer’s in 2019. This figure comprises an estimated 5.6 million people aged 65 and approximately 200,000 persons under 65 who have Alzheimer’s disease.
- Furthermore, 81% of the 5.8 million persons with Alzheimer’s dementia are 75 years or older. The number of Americans with Alzheimer’s disease is projected to climb as the size and share of the United States populace aged 65 and older endure to grow. According to the US Census Bureau, the number of Americans aged 65 and more will increase from 55 million in 2019 to 88 million by 2050. As a result, the market for Alzheimer’s disease diagnostics and therapies in the state is predicted to rise rapidly throughout the forecast period.
- Europe: The United Kingdom, Germany, France, Italy, Belgium, Poland, and Rest of Europe
- Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
- Rest of World: Latin America and Middle East & Africa
Major players in the global Alzheimer’s disease therapeutics & diagnostics market:
- Baxter International Inc
- GE Healthcare
- F Hoffmann-La Roche
- Novartis AG
- Pfizer Inc
Key strategies adopted by some of these companies:
Banner Alzheimer’s Institute collaborated with Eli Lilly and Company in July 2021 for a planned Phase 3 prevention trial of Donanemab.
In June 2021, US FDA granted Eisai and Biogen Inc’s Lecanemab (BAN2401), an Anti-Amyloid Beta Protofibril antibody for treating Alzheimer’s disease.
Report Synopsis:
| Report Scope | Details |
| Market Forecast Years | 2022-2030 |
| Base Year | 2021 |
| Market Historical Years | 2018-2021 |
| Forecast Units | Revenue ($ Million) |
| Segments Analyzed | Therapeutics & Diagnostics |
| Geographies Analyzed | North America, Europe, Asia-Pacific, and Rest of World |
| Companies Analyzed | Allergan PLC, Amarantus, BioScience Holdings Inc, Baxter International Inc, Biogen Inc, Cognoptix Inc, Eisai Co Ltd, Eli Lilly & Company, F Hoffmann-La Roche, GE Healthcare, Johnson & Johnson, Lupin Limited, Merck & Co Inc, Novartis AG, Pfizer Inc, Siemens Healthineers AG, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Limited, Zydus Cadila |
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- PARENT MARKET ANALYSIS
- KEY DRIVERS
- GROWING GERIATRIC POPULATION
- RISING PERVASIVENESS OF ALZHEIMER’S DISEASE
- EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
- INCREASING PIPELINE DRUGS
- KEY RESTRAINTS
- FAILURE OF THE LATE-STAGE DRUGS
- STRINGENT GOVERNMENT REGULATIONS
- LACK OF THE AVAILABILITY OF SURROGATE MARKERS
- KEY ANALYTICS
- TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
- PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
- IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
- BUYERS POWER
- SUPPLIERS POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- KEY BUYING CRITERIA
- SUPPLY CHAIN ANALYSIS
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- MARKET BY THERAPEUTICS & DIAGNOSTICS
- THERAPEUTICS
- DRUGS
- MARKETED DRUGS
- PIPELINE DRUGS
- DISEASE STAGE
- LATE-STAGE: SEVERE AD
- EARLY/MIDDLE STAGE: MILD TO MODERATE AD
- PRODROMAL STAGE
- GENERIC & BRANDED
- BRANDED
- GENERIC
- DRUGS
- DIAGNOSTICS
- LUMBAR PUNCTURE TEST
- POSITRON EMISSION TOMOGRAPHY
- ELECTROENCEPHALOGRAPHY
- MAGNETIC RESONANCE IMAGING
- COMPUTED TOMOGRAPHY
- BLOOD TEST
- OTHER DIAGNOSTICS
- THERAPEUTICS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED STATES
- CANADA
- EUROPE
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- BELGIUM
- POLAND
- REST OF EUROPE
- ASIA-PACIFIC
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- INDONESIA
- THAILAND
- VIETNAM
- AUSTRALIA & NEW ZEALAND
- REST OF ASIA-PACIFIC
- REST OF WORLD
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- REGIONAL ANALYSIS
- LATIN AMERICA
- MIDDLE EAST & AFRICA
- NORTH AMERICA
- COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
- MERGERS & ACQUISITIONS
- PRODUCT LAUNCHES & DEVELOPMENTS
- PARTNERSHIPS & AGREEMENTS
- BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
- COMPANY PROFILES
- ALLERGAN PLC (ACQUIRED BY ABBVIE)
- AMARANTUS BIOSCIENCE HOLDINGS INC
- BAXTER INTERNATIONAL INC
- BIOGEN INC
- COGNOPTIX INC
- EISAI CO LTD
- ELI LILLY & COMPANY
- F HOFFMANN-LA ROCHE
- GE HEALTHCARE
- JOHNSON & JOHNSON
- LUPIN LIMITED
- MERCK & CO INC
- NOVARTIS AG
- PFIZER INC
- SIEMENS HEALTHINEERS AG
- SUN PHARMACEUTICALS INDUSTRIES LTD
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- ZYDUS CADILA
- KEY STRATEGIC DEVELOPMENTS
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS
TABLE 2: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 3: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 8: GLOBAL MARKETED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 9: GLOBAL MARKETED DRUGS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 10: GLOBAL PIPELINE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 11: GLOBAL PIPELINE DRUGS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 13: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 14: GLOBAL LATE-STAGE: SEVERE AD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 15: GLOBAL LATE-STAGE: SEVERE AD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 16: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 17: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 18: GLOBAL PRODROMAL STAGE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 19: GLOBAL PRODROMAL STAGE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 20: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 21: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 22: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 23: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 24: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 25: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 26: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 27: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 28: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 29: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 30: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 31: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 32: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 33: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 34: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 35: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 36: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 37: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 38: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 39: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 40: GLOBAL BLOOD TEST MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 41: GLOBAL BLOOD TEST MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 42: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 43: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 44: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 45: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 46: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 47: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 48: LEADING PLAYERS OPERATING IN NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 49: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 50: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 51: LEADING PLAYERS OPERATING IN EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 52: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 53: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 54: LEADING PLAYERS OPERATING IN ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 55: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 56: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 57: LEADING PLAYERS OPERATING IN REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 58: LIST OF MERGERS & ACQUISITIONS
TABLE 59: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 60: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 61: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
LIST OF FIGURES
FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE
FIGURE 2: KEY MARKET TRENDS
FIGURE 3: PORTER’S FIVE FORCES ANALYSIS
FIGURE 4: KEY BUYING CRITERIA
FIGURE 5: SUPPLY CHAIN ANALYSIS
FIGURE 6: OPPORTUNITY MATRIX
FIGURE 7: VENDOR LANDSCAPE
FIGURE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021
FIGURE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)
FIGURE 10: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021
FIGURE 11: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)
FIGURE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)
FIGURE 13: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021
FIGURE 14: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)
FIGURE 15: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)
FIGURE 16: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)
FIGURE 17: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021
FIGURE 18: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)
FIGURE 19: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)
FIGURE 20: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)
FIGURE 21: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021
FIGURE 22: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)
FIGURE 23: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)
FIGURE 24: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)
FIGURE 25: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)
FIGURE 26: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)
FIGURE 27: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)
FIGURE 28: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)
FIGURE 29: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 30: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 31: CANADA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 32: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 33: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 34: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 35: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 36: ITALY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 37: BELGIUM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 38: POLAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 39: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 40: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 41: CHINA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 42: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 43: INDIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 44: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 45: INDONESIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 46: THAILAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 47: VIETNAM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 48: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 49: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 50: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)
FIGURE 51: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 52: MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
- MARKET BY THERAPEUTICS & DIAGNOSTICS
- THERAPEUTICS
- DRUGS
- MARKETED DRUGS
- PIPELINE DRUGS
- DISEASE STAGE
- LATE-STAGE: SEVERE AD
- EARLY/MIDDLE STAGE: MILD TO MODERATE AD
- PRODROMAL STAGE
- GENERIC & BRANDED
- BRANDED
- GENERIC
- DRUGS
- DIAGNOSTICS
- LUMBAR PUNCTURE TEST
- POSITRON EMISSION TOMOGRAPHY
- ELECTROENCEPHALOGRAPHY
- MAGNETIC RESONANCE IMAGING
- COMPUTED TOMOGRAPHY
- BLOOD TEST
- OTHER DIAGNOSTICS
- THERAPEUTICS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED STATES
- CANADA
- EUROPE
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- BELGIUM
- POLAND
- REST OF EUROPE
- ASIA-PACIFIC
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- INDONESIA
- THAILAND
- VIETNAM
- AUSTRALIA & NEW ZEALAND
- REST OF ASIA-PACIFIC
- REST OF WORLD
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- REGIONAL ANALYSIS
- LATIN AMERICA
- MIDDLE EAST & AFRICA
- NORTH AMERICA
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
Frequently Asked Questions (FAQs):
What was the worth of the North America Alzheimer’s disease therapeutics & diagnostics market in 2021?
The North America Alzheimer’s disease therapeutics & diagnostics market was valued at $2405.64 million in 2021.
Which is the fastest-growing disease stage in the global Alzheimer’s disease therapeutics & diagnostics market?
Prodromal stage is the fastest-growing disease stage in the global Alzheimer’s disease therapeutics & diagnostics market.
Which is the leading drug segment in the global Alzheimer’s disease therapeutics & diagnostics market?
Pipeline drugs are the leading drug segment in the global Alzheimer’s disease therapeutics & diagnostics market.
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.